Publications by authors named "R Yukawa"

We report the case of a 52-year-old male who presented to our hospital with cervical lymphadenopathy. Lymph node biopsy revealed small atypical lymphoid cells positive for CD3 and CD5 and negative for CD56 and Epstein-Barr virus (EBV)-encoded small RNA (EBER) by in situ hybridization. CD4-positive cells and CD8-positive cells were mixed in almost equal numbers.

View Article and Find Full Text PDF

The Kondo effect between localized f-electrons and conductive carriers leads to exotic physical phenomena. Among them, heavy-fermion (HF) systems, in which massive effective carriers appear due to the Kondo effect, have fascinated many researchers. Dimensionality is also an important characteristic of the HF system, especially because it is strongly related to quantum criticality.

View Article and Find Full Text PDF
Article Synopsis
  • * The patient's condition deteriorated despite initial treatment with azacitidine and corticosteroids, leading to increased myeloblasts and complications like organizing pneumonia and eosinophilia.
  • * The urgency for hematopoietic stem cell transplantation from his daughter highlights the poor prognosis associated with severe complications in MDS cases, particularly those with the der (1;7)(q10;p10) abnormality.
View Article and Find Full Text PDF

Primary effusion lymphoma-like lymphoma (PEL-LL) is a rare lymphoma, localized in the body cavity without detectable tumor masses. Tuberculous pleural effusion is a form of extra pulmonary tuberculous. We herein report three cases of PEL-LL in patients with a history of pulmonary tuberculosis.

View Article and Find Full Text PDF

Primary effusion lymphoma-like lymphoma (PEL-LL) shows a unique clinical presentation, characterized by lymphomatous effusions in the body cavities. PEL-LL may be associated with hepatitis C virus infections and fluid overload states; and owing to its rarity, no standard therapies have been established. We report a case of a 55-year-old woman who developed PEL-LL during treatment with dasatinib, for chronic myeloid leukemia (CML).

View Article and Find Full Text PDF